1. Volume 390, Issue 10110, Pages 2343-2345 (November 2017)
Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia 
Ehsan Ghorani, Baljeet Kaur, Rosemary A Fisher, Dee Short, Ulrika Joneborg, Joseph W Carlson, Ayse Akarca, Teresa Marafioti, Sergio A Quezada, Naveed Sarwar, Michael J Seckl 
The Lancet 
Volume 390, Issue 10110, Pages (November 2017)
DOI: /S (17)
Copyright © 2017 Elsevier Ltd Terms and Conditions

2. Figure Treatments, response, and immune phenotyping for patient 1
(A) Serum hCG concentration measured throughout treatment. Shaded bands represent duration of chemotherapy and immunotherapy with (a) low dose EP, (b) EP/EMA, (c) TE/TP, (d) tandem high-dose chemotherapy, (e) escalated EP, and (f) gem-TIP. Arrowheads show treatment dates. Therapeutic regimens are summarised in the appendix (p 4). (B) Multiplex immunohistochemistry of the tumour immune landscape shows dense lymphocyte infiltration of cells expressing CD4, PD1, FOXP3 (regulatory T cells that coexpress CD4), and CD8. Further characterisation is shown in the appendix (p 5). hCG=human chorionic gonadotropin. EP=etoposide and cisplatin. EP/EMA=etoposide and cisplatin alternating with etoposide, methotrexate, and dactinomycin. TE/TP=etoposide and paclitaxel alternating with cisplatin and paclitaxel. gem-TIP= gemcitabine, paclitaxel, ifosfamide, and cisplatin.
The Lancet  , DOI: ( /S (17) )
Copyright © 2017 Elsevier Ltd Terms and Conditions